Prevention of progression in chronic myeloid leukemia by altering DNA methylation with a pyridoxine analogue.
Altered DNA methylation is one mechanism by which progression might occur in tumors. Progression in chronic myeloid leukemia (CML) was initially thought to be due to mutations. However, altered DNA methylation might be responsible for the same. An agent whose probable target is DNA methylation has been shown to improve hematopoiesis in CML. Pyridoxine is involved in methylation reactions. At present, the link between dietary factors like pyridoxine and cancer is somewhat tenuous. It is hypothesized that a suitable pyridoxine analogue might, by blocking DNA methylation, prevent progression in CML.
Sastry
P S
PS
D019175:DNA Methylation / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism*; D008954:Models, Biological; D011736:Pyridoxine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D004273:DNA, Neoplasm; D011736:Pyridoxine